Active, not recruiting. The drug demonstrated a high safety profile, with no serious toxicities (DLT) and ≥3 grade adverse events. Despite low doses, PNT6555 confirms its promise as a precise and safe therapy for tumors with high FAP expression, including melanoma, requiring refinement to improve efficacy. This evidence concerns the gene FAP and melanoma.